UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
March 27, 2006
Date of Report (Date of earliest event reported)
-----------------------------------------------------------
ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
-----------------------------------------------------------
State of New York 1-10113 11-0853640
(State of Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification Number)
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)
(847) 705-7709
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d- 2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17CFR 240.13e- 4(c))
Item 8.01 Other Events
As disclosed in the Registrant's Form 8-K filed with the Commission on
January 31, 2006, the Registrant borrowed $750,000 pursuant to a Loan Agreement
dated as of January 31, 2006 with various lenders (the "Bridge Lenders"). The
Loan Agreement also permitted additional loan advances to the Registrant. On
March 27, 2006, the Bridge Lenders extended the Registrant an additional
$750,000 in loans, pursuant to the Loan Agreement.
Item 9.01 Financial Statements and Exhibits
Exhibit Number Description
- -------------- -----------
99.1 Press Release dated March 27, 2006 Announcing Receipt of
Interim Funding
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ACURA PHARMACEUTICALS, INC.
By: /s/ Peter Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer
Date: March 27, 2006
Exhibit Index
Exhibit Number Description
- -------------- -----------
99.1 Press Release dated March 27, 2006 Announcing Receipt of
Interim Funding